TD Cowen analyst Josh Jennings maintains $Boston Scientific (BSX.US)$ with a buy rating, and maintains the target price at $100.
According to TipRanks data, the analyst has a success rate of 54.6% and a total average return of 4.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has presented a quarter that exceeded forecasts on all fronts, in spite of already lofty anticipations. Nonetheless, the company's shares are currently experiencing pressure due to the temporary halt of the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient cohort. It is essential to note that the affected patient segment is not currently receiving treatment, that there are certain observations under evaluation, and that the enrollment for the study is anticipated to recommence shortly.
Boston Scientific's Q3 outcomes were characterized as 'impressive,' coinciding with an elevation in management's 2024 guidance, now forecasting an exit with +15% organic sales growth. The company's stock experienced a decline following a temporary halt in an EP trial, AVANTGUARD. However, this reaction is considered to be exaggerated when taking into account insights from key opinion leaders.
The setback in the AVANT Guard trial is not associated with a mortality event or triggered by regulatory authority, and the momentum for global Farapulse is considered sustainable over the medium term. It is believed that the recent decline in Boston Scientific shares offers an attractive entry point for investors.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析师Josh Jennings维持$波士顿科学 (BSX.US)$买入评级，维持目标价100美元。
根据TipRanks数据显示，该分析师近一年总胜率为54.6%，总平均回报率为4.5%。
此外，综合报道，$波士顿科学 (BSX.US)$近期主要分析师观点如下：
波士顿科学已经提出了一个在各方面都超出预期的季度，尽管已经有很高的期望。然而，由于AVANt GUARD临床试验的暂时暂停，该试验正在研究Farapulse在新的患者群中的应用，公司股票目前正面临压力。重要的是要注意，受影响的患者群目前未接受治疗，有一些观察结果正在评估中，并且预计该研究的招募很快将重新开始。
波士顿科学的第三季度业绩被描述为“令人印象深刻”，与管理层2024年预测的+15%有机销售增长的提升相吻合。公司股票在暂停EP试验AVANTGUARD后出现了下滑。然而，考虑到来自主要意见领袖的见解，这种反应被认为是夸大的。
AVANt Guard试验的挫折与死亡事件无关，也不是由监管机构触发的，全球Farapulse的势头被认为在中期内是可持续的。有人认为波士顿科学股价最近的下降为投资者提供了一个有吸引力的入场点。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
